Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timolol Nasal Spray for Epistaxis in HHT
DRKS00020994Phase 2Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of timolol in hereditary hemorrhagic telangiectasia (HHT) and epistaxis (2 arms), sponsored by Universitätsklinikum Regensburg. Started Mar 2020; status: completed.
02
Drugs
timolol
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on DRKS00020994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00020994.